The One Step NMP22 Test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (NUMA), which is an abundant component of the nuclear matrix proteins, in the urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer. This assay provides only a preliminary result. Clinical expertise and professional judgment should be sought to further evaluate the result of the test.

Zhejiang Orient Gene Biotech Co., Ltd specializes in the R&D, production, and sales of in vitro diagnostic products in the field of high-end medical equipment and devices.
Currently, its main products are POCT instant diagnostic reagents, which are mainly used in the detection of infectious diseases (including COVID-19 detection products), drugs of abuse, fertility, tumor marker and cardiac marker detection, among which infectious disease and drugs of abuse detection are the two core product series of the company.
The company’s sales network has been extended to more than 120 countries and regions, and its overseas sales revenue accounted for 95% in 2019. At present, the company has obtained more than 300 overseas certifications/records, and more than 70 domestic registration/record certificates.